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SIGNIFICANCE
Biologics are effective medications for psoriasis. Dose re-
duction of biologics for psoriasis could contribute to more 
personalized treatment. This study evaluated a one-step 
biologic dose reduction strategy in daily practice. The dose 
was reduced in 80 psoriasis patients with adequate disease 
control using adalimumab, etanercept or ustekinumab for 
at least 6 months. Patients could return to their normal dose 
in case of disease flare. After 1 year, 67% of patients were 
still on a lower dose. Cumulative dose and costs decreased. 
Therefore, a one-step tightly controlled dose reduction 
strategy for adalimumab, etanercept and ustekinumab has 
considerable potential to decrease biologic dosages.
Dose reduction of biologics for psoriasis could contri-
bute to lower drug exposure. This study evaluated a 
one-step, tightly controlled, biologic dose reduction 
strategy in a prospective daily practice cohort. In pa-
tients with psoriasis with low disease activity using 
adalimumab, etanercept or ustekinumab for at least 6 
months, the dosing interval was prolonged with 33%. 
Patients could return to their normal dosing interval in 
case of disease flare. Of 108 eligible patients, 80 star-
ted dose reduction and were analysed. In total, 36/80 
patients (45.0%) discontinued dose reduction after 19 
months (95% confidence interval 14.9–23.1 months). 
Of 67 patients with 1-year follow-up, 45 (67.2%) still 
used the lower dose after 1 year. No serious adverse 
events related to dose reduction occurred. Cumulative 
dose and costs decreased by 22.7% during 1 year. In 
conclusion, a one-step tightly controlled dose reduc-
tion strategy for adalimumab, etanercept and uste-
kinumab has considerable potential to safely decrease 
biologic dosages in patients with psoriasis in daily 
practice. 
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Biologics are effective therapies for moderate-to-severe psoriasis. However, treatment with biologics 
is often based on general guidelines and standard dosing 
regimens. This may not always suit the individual patient. 
Dose reduction (DR) of biologics in psoriasis could 
contribute to more personalized treatment. High costs 
and long-term safety concerns associated with biologics 
make DR desirable for implementation in daily practice. 
In a recent pragmatic randomized controlled trial 
(RCT) we investigated a tightly controlled DR strategy 
in patients with psoriasis with stable low disease acti-
vity: the CONDOR study (1). Although non-inferiority 
regarding disease activity was not demonstrated, DR 
of adalimumab, etanercept, and ustekinumab was pos-
sible in 53% of patients, without safety concerns. Other 
studies also showed that DR of adalimumab, etanercept 
and ustekinumab is possible in patients with low disease 
activity (2–5), but success rates differ based on success 
definition, DR strategy and study design. 
For further implementation of such a strategy, it is 
essential to study the gains and investments needed in 
daily practice. Therefore, the aim of this study was to 
prospectively evaluate a one-step tightly controlled DR 
strategy in daily practice. This strategy, based on the 
CONDOR study, was incorporated in clinical practice. 
The strategy is guided by disease activity and patients’ 
reported quality of life (QoL). Instead of 2 DR steps 
in CONDOR, we started conservatively with only one 
step, leading to 67% of the original dose. The use of 
this adapted, one-step tightly controlled DR strategy in 
daily practice was evaluated regarding time investment, 
practicability, patients’ experiences, success rate, patient 
and treatment characteristics, safety and cost reduction. 
MATERIALS AND METHODS
Design and participants
This prospective, clinical evaluation was conducted at the depart-
ment of dermatology of Radboudumc, an academic hospital in the 
Netherlands, between February 2018 and February 2020. The tight-
ly controlled DR strategy of the CONDOR study was adapted and 
evaluated in clinical practice in our hospital after retrieving first 
trial results (1). In CONDOR, eligible patients had Psoriasis Area 
and Severity Index (PASI) scores ≤ 5 at 2 subsequent visits in the 
past 6 months and Dermatology Life Quality Index (DLQI) scores 
≤ 5 at inclusion. In our daily practice strategy, patients were asked 
to participate in case of low disease activity for at least 6 months 
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according to the treating physician, with PASI and DLQI scores 
≤ 5 at start of DR. Participation on patients’ request despite PASI 
or DLQI > 5 or treatment < 6 months was allowed after approval 
from their treating physicians. In accordance with the trial, adult 
patients with plaque psoriasis as primary indication for biologic 
use, should use adalimumab, etanercept or ustekinumab at the 
registered dose (40 mg every other week, 50 mg per week, 45 mg 
or 90 mg every 12 weeks, respectively) for at least 6 months 
before starting DR. In case of psoriatic arthritis (PsA), patients 
should have adequately controlled joint inflammation. The trea-
ting rheumatologist was consulted for approval of DR in case of 
doubt. The use of concomitant anti-psoriatic drugs was permitted. 
Instead of 2 DR steps, DR was started conservatively with only 
one step. The interval was prolonged, leading to 67% of the origi-
nal dose. In case of a disease flare (i.e. PASI and/or DLQI score 
> 5), patients were advised to return to the (previous) effective or 
authorized dose of their biologic. Patients could also return to the 
(previous) effective dose at their own request. 
All patients at our outpatient clinic for biological treatment were 
screened by a dedicated nurse, to determine whether they were 
possible candidates for DR. In case of a negative first screening 
result, patients were screened again before every subsequent 
visit. Possible eligible patients were asked to participate by their 
treating physician (i.e. shared decision-making). Patients’ moti-
vations for participating in the strategy and for not participating 
were collected. 
Outpatient visits took place every 3–6 months with monitoring 
of disease activity by PASI and DLQI, according to usual prac-
tice. Extra visits could be scheduled at patients’ request. Patients 
were also asked to complete the Skindex-29 questionnaire, a 
dermatology-specific quality of life questionnaire (6–8). During 
follow-up, patients were asked about their experiences with the 
DR strategy, as well as their reasons for discontinuation of DR. 
Patients were stimulated to contact their physician in case of 
disease worsening. When patients were not able to visit the clinic, 
a telephone contact was made. Safety monitoring was carried out 
according to existing guidelines for clinical practice, and serious 
adverse events (SAEs) possibly related to DR were collected. 
All data were anonymized and collected using a web-based 
data management system, CASTOR (9). All patients have been 
included in the prospective BioCAPTURE registry, as described 
elsewhere (10), and therefore provided written informed consent 
to use their clinical data for scientific purposes.
Outcomes
The aim of this study was to evaluate the use of the adapted DR 
strategy in daily practice. Therefore, the numbers of patients eli-
gible for DR were analysed. Patients’ opinions and experiences 
were assessed, including reasons for participating and for not 
participating, and reasons for stopping DR. The success of the DR 
strategy was measured by the proportion of patients using a lower 
biologic dose up to 1 year, and the proportion of patients who stop-
ped DR including time until stop. Regarding safety, SAEs possibly 
related to DR were assessed. Furthermore, disease activity (PASI 
scores) and patient-reported quality of life (DLQI and Skindex-29 
scores) during 1 year of DR were evaluated. Cumulative reduced 
biologic doses and costs were compared with the normal doses. 
Other indirect costs, such as other medical costs or visit costs, 
were not included. Biologic costs were based on actual Dutch 
prices during the study (11).
Statistical analysis
Data were extracted from the database and imported into SPSS 
Statistics 25 (IBM, Armonk, NY, USA) for analysis. Patients who 
stopped DR ≤ 1 month and patients who were included < 3 months 
before data lock were excluded from analyses. Follow-up ended 
when patients discontinued DR or at the moment of data lock, 
whichever came first. Depending on the type of variable and its 
distribution, descriptive statistics are presented as percentages 
with absolute numbers, means with 95% confidence intervals 
(95% CI) or medians and interquartile ranges (IQR). In order to 
analyse outcomes for different time-points, visit data were centred 
into the nearest 3-monthly time-points (i.e. visit months) with a 
window of ± 6 weeks.
Screening results of patients possibly eligible for DR were 
summarized, and the number needed to screen (NNS) of all 
patients from the biologic outpatient clinic to detect one pa-
tient who started DR was calculated. Baseline characteristics 
of participating patients were summarized, as well as patients’ 
motivations for participation or refusing participation, patients’ 
experiences regarding DR, proportion of patients on a lower dose, 
proportion of patients who stopped DR (for the total cohort and 
per biologic), and reasons for stopping DR. The time until stop 
of DR was presented graphically by a Kaplan–Meier curve and 
patients were censored when follow-up ended. Median survival 
time was calculated for the total group and per biologic. Based 
on PASI and DLQI scores at the moment of DR discontinuation, 
the total number of patients who stopped due to a disease flare 
(i.e. PASI and/or DLQI > 5) was calculated. Of patients with PASI 
> 5, further PASI course for the next 6 months was checked in 
their patient records. The proportion of patients who discontinued 
DR despite low PASI and/or DLQI scores was also calculated. 
SAEs possibly related to DR (e.g. psoriasis exacerbation requiring 
hospitalization) were counted.
For subanalyses of outcomes after 1 year, a subcohort of pa-
tients with sufficient follow-up was defined, including patients 
who started the DR strategy ≥ 1 year ago. For this subcohort, the 
proportion of patients who were still on a lower dose after 1 year 
was calculated. PASI, DLQI and Skindex-29 were analysed in 2 
ways. First, data of continuing patients only were analysed (“as 
treated” analysis), and second, “intention to treat” (ITT) analysis 
with imputation of missing values using last observation carried 
forward (LOCF) was performed on the total group. The LOCF 
method carries forward the last available outcome, which leads to 
more conservative estimations (12). The dose used in the first year 
of the DR strategy was calculated for the subcohort of patients 
who started DR ≥ 1 year ago. In case patients discontinued DR, 
their used dose during the rest of the year was substituted. The 
mean reduction in the biologic dose compared with the normal 
dose per label, and corresponding cost reduction, were calculated. 
RESULTS 
Participants
In total 498 patients visiting our outpatient clinic for 
biological treatment were screened between February 
2018 and February 2020. The screening results are 
shown in Fig. 1. In total, 390 out of 498 patients did 
not qualify for DR, for the reasons stated in Fig. 1. This 
resulted in a group of 108 patients eligible for DR. After 
re-screening of 390 ineligible patients, 15 patients were 
included because they achieved stable disease activity, 
used normal doses again, reached 6 months treatment 
duration or because of other reasons. In total, 85 out of 
498 (total clinic population) started with DR, resulting in 
a NNS for one patient on DR of 5.9. Five patients were 
excluded from analysis (see Fig. 1). The total follow-up 
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A subcohort of 67 patients who started the DR strategy 
≥ 1 year ago was defined for subanalyses. The time in-
vestment of the dedicated nurse was approximately 1 h 
per 16 patients. Baseline characteristics of the partici-
pating patients are shown in Table I. Overall, baseline 
PASI and DLQI scores were low. However, 3 patients 
started DR at their own request with DLQI scores > 5. 
One patient insisted on starting DR despite PASI > 5, but 
had a limited affected body surface area (2.3%) and a 
DLQI score of 0 and was therefore allowed to start DR. 
Patients’ opinions and experiences
Patients’ reported motivations for participating are shown 
in Table II. The most important reason for starting DR 
was “minimizing medication use”. Of all patients who 
did not want to participate, the most frequently reported 
reason was “fear of psoriasis flares”. During follow-up, a 
random sample of 55 participants were asked about their 
experiences. Of this sample, 36 patients (65.5%) were 
positive or satisfied regarding DR, 13 patients (23.6%) 
were slightly positive/moderately satisfied, and 6 patients 
did not respond. No participants were dissatisfied.
Dose reduction characteristics
Of all patients who started DR (n = 80), regardless of 
their follow-up duration, 44 (55%) continued and 36 
(45%) discontinued DR. DR was stopped by 19/42 
(45.2%) adalimumab patients, 7/16 (43.8%) etanercept 
patients and 10/22 (45.6%) ustekinumab patients. The 
number of patients who discontinued DR per visit month 
is shown in Table III. In total, 7/36 discontinuing pa-
tients had PASI and/or DLQI scores > 5, whereas 22/36 
patients discontinued DR despite low PASI and/or DLQI 
Total number of patients (n=498)  
Ineligible (n=390) 
New patient (n=117)  
Other biologic (n=72) 
Unstable disease (n=59) 
On increased dose (n=34) 
Less than 6 months on biologic (n=34) 
On decreased dose (n=25) 
Previous attempt to reduce dose failed 
(n=15) 
Other reason (n=34) 
Patients excluded (n=38) 
Patients opt out (n=34) 
Unstable disease (n=4)  
Assessed for eligibility (n=108) 
Patients included for participation 
(n=85)  
Patients excluded in analyses (n=5)  
No follow up visit (n=3) 
Stopped dose reduction <1 month 
(n=2) 
Patients included in analyses (n=80) 
Adalimumab (n=42) 
Etanercept (n=16) 
Ustekinumab (n=22)  
Eligible after re-screening (n=15) 
 
 
Eligible patients (n=70)  
Patients that started the dose 












Fig. 1. Screening results and eligible patients. Patients with psoriasis 
who visited the outpatient clinic for biological treatment were screened 
between February 2018 and February 2020. Only patients with stable, low 
disease activity for at least 6 months and using adalimumab, etanercept or 
ustekinumab at the normal, registered dose could participate.
Table I. Baseline characteristics of participating patients
Characteristics Total (n = 80)
Sex, male, n (%) 57 (71.3)
Age, years, median (IQR) 52 (43–64)
BMI, kg/m2, median (IQR) 28.2 (21.4–31.7)a
Baseline PASI score, median (IQR) 1.6 (0–2.4)b
Baseline DLQI score, median (IQR) 0 (0–1)c
Baseline Skindex-29 score, median (IQR) 4.7 (0.9–13.8)d
Treatment, n (%)
  Adalimumab 42 (52.5)
  Ustekinumab 22 (27.5)
  Etanercept 16 (20)
Comorbidities, yes, n (%) 
  Psoriatic arthritis 16 (20)
  Rheumatoid arthritis 2 (2.5)
  Spondylarthropathy 2 (2.5)
  Hidradenitis suppurativa 1 (1.3)
  Inflammatory bowel disease 0
  Other 3 (3.8)
Co-medication, n (%)
  Methotrexate/acitretin 5 (6.3)
  Azathioprine/prednisolone 1 (1.3)
Missing data (n): a12, b3, c2, d3.
BMI: body mass index; DLQI: Dermatology Life Quality Index; IQR: interquartile 
range; PASI: Psoriasis Area and Severity Index; SD: standard deviation.
Table II. Reasons for participating (n = 80)
Reason n (%)a
Predefined answers
  To use a minimum amount of medication 47 (58.8)
  Biologic use for a long time 18 (22.5)
  To lower societal healthcare costs 12 (15)
  Afraid of long-term effects 10 (12.5)
  Experiencing side-effects 7 (8.8)
Open answers 
  Stable low disease activity 9 (11.3)
  According to suggestion treating physician 7 (8.8)
  To contribute to research 3 (3.8)
  Possible positive health effects 3 (3.8)
  To see if skin remains clear 2 (2.5)
  Why not 1 (1.3)
  Patients request 1 (1.3)
  Asked, but unknown 1 (1.3)
aData are presented as n (% of total participants). More answers were possible.
Table III. Numbers of patients who discontinued dose reduction 
(DR) per visit month 
Time, monthsa
Total3 6 9 12 15 18 21
Stop DR 14 6 6 1 4 2 3 36
  PASI and/or DLQI >5 4 1 1 1 – – –   7 (19.4%)b
  PASI and/or DLQI ≤5 8 4 3 – 2 2 3 22 (61.1%)b
  Unknown PASI and/or DLQI 2 1 2 – 2 – –   7 (19.4%)b
aData are presented as number of patients in the total cohort (n = 80) who 
discontinued DR per visit month during follow-up. bPercentage of patients who 
discontinued DR.
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scores. Two patients stopped DR due to an increase in 
joint complaints, with one patient already having PsA. 
Rheumatological examination of the other patient did 
not reveal PsA. During follow-up, a total of 8 patients 
temporarily showed a PASI > 5, of which 4 patients 
continued DR at their own request and regained PASI 
< 5 within 6 months. Of 4 patients with PASI > 5 who 
discontinued DR, 3 patients regained PASI < 5 within 6 
months. One patient with baseline PASI > 5 discontinued 
DR at 6 months (PASI > 5). All patients with high ba-
seline DLQIs (n = 3) discontinued DR at month 3, with 
one patient having PASI > 5. The median time until stop 
was 19 months (95% CI 14.9–23.1) as presented in a 
Kaplan–Meier curve (Fig. 2). Reasons for stopping DR 
were reduced effectiveness experienced by the patient 
(n = 18; 50%), reduced effectiveness experienced by 
both physician and patient (n = 9; 25%), joint complaints 
(n = 2; 5.6%), or another reason/missing (n = 7; 19.4%). 
No serious adverse events (SAEs) related to DR were 
reported. There were no changes in concomitant im-
munosuppressant use. 
From the subcohort of patients who started DR ≥ 1 
year ago (n = 67), 45 patients (67.2%) were still on a 
lower dose after 1 year. Twenty-seven out of 37 (72.9%) 
adalimumab patients, 8/14 etanercept patients (57.1%) 
and 10/16 (62.5%) ustekinumab patients were on a lower 
dose after 1 year. 
Disease activity and quality of life
PASI, DLQI and Skindex-29 during 1 year were analysed 
in 2 ways (as treated and ITT with LOCF) as shown in 
Fig. 3. Analyses were performed within the subcohort 
of patients who started DR ≥ 1 year ago (n = 67). During 
1 year of DR, PASI scores were low (median [IQR], 1.6 
[0.2–2.5] at baseline, 1.7 [0.5–3.0] at month 6 and 1.9 
[0.8–2.8] at month 12 in as treated analyses) with a maxi-
mum range of 0–6.9. Median DLQI scores (as treated) 
were 0 [0–1] at baseline, 0 [0–1.5] at month 6 and 0.5 
[0–2] at month 12. For Skindex-29, median scores (as 
treated) were 5.2 [0.9–16.4] at baseline, 5.2 [0.9–13.8] 
at month 6 and 6.9 [0.9–14.7] at month 12. Both median 
DLQI and Skindex scores correspond with minimal im-
pact of psoriasis on patients’ QoL (13, 14). ITT analysis 
with LOCF gave a more conservative estimate of PASI, 
DLQI and Skindex-29, with slightly higher scores after 
month 6 compared with the as treated analysis. 
Fig. 2. Kaplan–Meier survival curves for time until stop of dose reduction (DR). (a) Time until stop of DR for all biologics (n = 80). Median time 
until stop was 19 months (95% CI 14.9–23.1 months). (b) Time until stop of DR split per biologic. Data include 42 patients on adalimumab (ADA) (n = 19 
stopped DR), 16 on etanercept (ETA) (n = 7 stopped DR) and 22 on ustekinumab (USTE) (n = 10 stopped DR). Median time until stop was 9 months (95% 
CI 14.7–23.3 months) for adalimumab, and 19 months (95% CI 12.0–26.0 months) for ustekinumab. For etanercept, the median time until stop of DR 
could not be calculated, as > 50% was still active in the survival curve at end of analysis.
Fig. 3. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and Skindex-29 scores by analysis method. 
Total number of patients n = 67. Data are presented as medians with interquartile range (IQR). Range of total possible scores: PASI 0–72, DLQI 0–30, 
Skindex-29 0–100. Number of missing observations per visit month for the as treated analyses (n): PASI 3 (month 0), 3 (month 3), 1 (month 6), 2 
(month 9), 1 (month 12); DLQI 1 (month 0), 3 (month 3), 1 (month 6), 0 (month 9), 3 (month 12); Skindex-29 8 (month 0), 2 (month 3), 2 (month 
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Biologic doses and costs 
The cumulative dose during 1 year of the DR strategy 
was calculated for the subcohort of patients who started 
DR ≥ 1 year ago (n = 67). In total, a 22.7% reduction 
in biologic dose and costs was achieved after 1 year 
compared with the per label dose, resulting in absolute 
cost savings of €159,228.16. Mean dose per patient per 
biologic, cost savings and the corresponding percentage 
reduction are shown in Fig. 4. 
DISCUSSION
This prospective evaluation shows that a one-step tightly 
controlled DR strategy of adalimumab, etanercept and 
ustekinumab for patients with psoriasis is possible in 
daily practice. Of 108 patients with low disease activity, 
85 started DR. The most important reason among patients 
for starting DR was “minimizing medication use”, where-
as for not participating this was “fear of psoriasis flares”. 
After 1 year, 67% of patients were still on a lower dose. 
QoL and disease activity remained stable, and no SAEs 
related to DR occurred. Of patients with temporary PASI 
> 5, disease remission was regained in the vast majority 
of patients. Consequently, direct medication costs were 
reduced substantially by 22.7%. 
The DR strategy described here was based on a RCT 
on tightly controlled DR of adalimumab, etanercept and 
ustekinumab in patients with psoriasis (CONDOR) (1). 
In the current study this strategy was adapted in order to 
make it more applicable for daily use. Inclusion criteria 
were less strict, the approach was more patient driven 
and the current study used only one step of DR (33% 
decrease of the normal dose) instead of 2 steps (50% 
decrease of the normal dose). The reason for this adapta-
tion was that, in our early experience with the CONDOR 
study, the majority of patients successfully achieved this 
first step of DR. Furthermore, one step is more practical. 
It might be easier to convince patients to decrease their 
biologic dose by only 33%. In this clinical evaluation, a 
similar proportion of patients used a lower biologic dose 
after 1 year compared with the trial: 67% vs 68% in the 
trial. The mean cumulative dose used in 1 year was less 
reduced than in CONDOR, which can be explained by 
the adapted strategy. With the final results of CONDOR 
we now know that 34% of patients achieved the second 
step of DR to 50% of the original dose (1). Therefore, if 
one-step DR is successful, a further decrease should be 
discussed with the patient.
In line with these results, previous studies indicated 
that DR of biologics for psoriasis is possible. In these 
studies, patients could also reduce their dose after ap-
proximately 6 months and in case of low disease activity, 
but success rates ranged from 22% to 90% depending 
on the definition of success and the study design (2–5). 
The current evaluation differs from previous studies, as 
it prospectively evaluated a modified, tightly controlled 
strategy from a recently conducted RCT (1). We believe 
that tight control is needed in order to safely determine 
the lowest effective dose. Moreover, this study elucidates 
the investments needed to perform DR on a standard 
basis in clinical practice. A dedicated nurse was pro-
vided to support physicians and patients. This made it 
possible to collect data and it improved applicability of 
the strategy. The nurse screened all patients visiting our 
biologic outpatient clinic, with a time investment of 1 h 
per 16 patients. Of all 498 visiting patients, 85 eventually 
started DR, resulting in a number needed to screen of 5.9 
patients. Of 498 patients however, most patients were not 
eligible, as they did not use a biologic yet, had unstable 
disease, or used another biologic. Patients needed to be 
screened several times, as disease activity could become 
stable over time. This requires time investment. Instal-
ling a dedicated nurse or physician could contribute to 
the success of a new strategy, as coaching of patients is 
needed. Of the patients who stopped DR, 66% had a PASI 
and/or DLQI ≤ 5, and reduced effectiveness experienced 
by the patient, while not experienced by the physician, 
Fig. 4. Mean doses per patient and percentage reduction in normal dose and costs after 1 year of dose reduction (DR) strategy. Data are 
presented for the subcohort of patients who started DR ≥ 1 year ago (n = 67). Cost savings are presented as mean per patient and were based on actual 
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contributed the most among reasons for stopping DR. 
It was possible for patients to stop DR on their request 
due to several reasons, such as fear of disease flare. On 
the other hand, one patient wanted to start DR with a 
PASI > 5. Four patients continued DR despite PASI > 5. 
Personalizing treatment goals and coaching of patients 
therefore seems important when considering DR. 
Currently, the possibility of DR is mentioned in only 
a few published national guidelines (15, 16). No clear 
protocols are available yet. A tightly controlled strategy, 
guided by disease activity and QoL, seems safe for 
daily use and allows evaluation of the success of the 
strategy. In the current strategy we used a PASI and/or 
DLQI score ≤ 5 as target for starting and continuing DR. 
It can be questioned whether this is the correct target, 
as in the field of psoriasis different treatment targets 
were defined in recent years. For example, the National 
Psoriasis Foundation defined their therapeutic goal as a 
body surface area of 1% or less (17), while a Spanish 
group recommended a PASI 90 or Physicians’ Global 
Assessment (PGA) ≤ 1, with a DLQI ≤ 1, and prolonged 
remission without loss of response and worsening of 
comorbidities (18). In Belgium, the target was multi-
dimensional, including multiple criteria, such as disease 
activity, itch, DLQI, daily functioning and safety (19). 
Mahil et al. (20) recently stated that PASI ≤ 2 and PGA 
clear/almost clear are relevant for treat to target strate-
gies. In our opinion however, not only disease activity, 
but also QoL, should be taken into account, as it might 
differ among patients as to which PASI scores are ac-
ceptable (21). Therefore a low DLQI was a prerequisite, 
apart from PASI. Moreover, PASI is difficult to assess at 
lower score levels (22). Some patients with higher PASIs 
may still have limited disease activity and DLQI may be 
informative in this context. 
A limitation of this evaluation is the study length in 
the context of long-term gains and risks of DR. How-
ever, in the current evaluation no safety issues related 
to DR occurred. Furthermore, 7/8 patients with PASI 
> 5 during the analysis period regained PASI < 5 within 
6 months. Only 2 patients discontinued DR due to an 
increase in joint complaints, with one patient having 
PsA. The outcomes of DR regarding other inflammatory 
comorbidities were not assessed, although, according to 
clinical practice, DR was reconsidered in case of worse-
ning of such comorbidities. Studying the effect of DR on 
comorbidities specifically is for future research. In line 
with the current results, previous studies did not report 
safety issues related to DR, despite follow-up might 
not have been long enough for assessing all adverse 
outcomes (23). The long-term extension results of our 
previous RCT showed a temporary, small increase in 
PASI scores, which decreased again after 18 months (24). 
No patients who failed on DR needed to switch treatment 
within 24 months of follow-up, as treatment responses 
were regained by re-installing the normal dose. Impact 
on QoL remained low and there were no safety signals, 
including symptoms related to anti-drug antibody forma-
tion (24). Another study found no difference in develop-
ment of anti-drug antibodies of ustekinumab between 
patients on a reduced dose vs the normal dose (4). It 
should be emphasized that, by striving for tight control, 
timely dose adjustments can lead to re-achievement of 
adequate treatment responses, hence limiting long-term 
safety risks. Still, more long-term data regarding DR is 
needed in order to provide insight into longer term risks 
and benefits. 
A further limitation of the current study is that it did not 
analyse the use of topical steroids or other health-related 
costs. Consequently, indirect costs related to DR could 
not be calculated. In our previous RCT, more patients in 
the DR group used topical steroids compared with the 
usual care group, and healthcare usage was higher (1, 
25). However, the DR strategy resulted in substantial 
cost savings, with a minimal reduction in quality-adjusted 
life years. 
In our opinion, this clinical evaluation shows that a 
pragmatic, one-step DR strategy of adalimumab, etaner-
cept and ustekinumab for psoriasis is possible in daily 
practice. Seventy-eight percent of eligible patients started 
DR. Two-thirds of patients who started DR at least 1 year 
ago were still on a lower dose after 1 year, without safety 
concerns. Although it requires some time investment, 
the study showed that even a one-step DR strategy has 
considerable potential to lower cumulative biologic doses 
with lowering of healthcare costs, without deterioration 
of psoriasis. More daily practice studies with longer 
follow-up of patients could contribute to accumulation 
of evidence regarding biologic DR.
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